Date: 2012-04-17
Type of information: Grant
Company: to-BBB (The Netherlands)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount:
Funding type: grant
Planned used: The financing will be used to conduct preclinical research targeting neuroinflammation in Parkinson’s disease (PD) with to-BBB\'s second product in development, 2B3-201.
Others: to-BBB, the Dutch brain drug delivery company, has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct preclinical research targeting neuroinflammation in Parkinson’s disease (PD) with its second product in development, 2B3-201. This is to-BBB’s first grant from MJFF.
to-BBB aims to demonstrate the improved effect of its brain-targeted long-circulating liposomal formulation of methylprednisolone (2B3-201) in established preclinical models of PD. Methylprednisolone is known to be a very effective drug in reducing acute neuroinflammation, however, its widespread use is limited by the well-known acute and chronic side effects of glucocorticoids. In preliminary preclinical studies, 2B3-201 has already shown to significantly better reduce neuroinflammation in preclinical models as compared to similar doses of free methylprednisolone. This was accomplished by a sustained higher brain penetration at a low effective dose, with demonstrable less side effects, thereby significantly improving the therapeutic index of the treatment.
Therapeutic area: Neurodegenerative diseases
